SCHEDULE: Vanguard Group Amends Sarepta Therapeutics Ownership Report

The Vanguard Group has amended its Schedule 13G filing for Sarepta Therapeutics, reporting 0% beneficial ownership due to an internal reporting realignment.

Summary

• The Vanguard Group filed an Amendment No. 12 to its Schedule 13G for Sarepta Therapeutics Inc. common stock.
• The filing reports 0% beneficial ownership of Sarepta Therapeutics common stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following the realignment, certain Vanguard subsidiaries or business divisions will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update, reflecting a change in The Vanguard Group's internal reporting structure rather than a material change in their investment in Sarepta Therapeutics or the company's fundamentals.

Future Outlook

No forward-looking statements or guidance regarding Sarepta Therapeutics are provided in this administrative filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, indicating passive investment intent. Amendments, like this one, often reflect changes in ownership thresholds or, as in this case, internal reporting structures rather than a change in investment strategy or a full divestment by the broader institutional family.

Key Dates

Keywords

Sarepta Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Common Stock, Reporting Realignment